Ooms Marcel, Letko Michael, Simon Viviana
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
J Virol. 2017 Feb 14;91(5). doi: 10.1128/JVI.02289-16. Print 2017 Mar 1.
Human APOBEC3H (A3H) is a cytidine deaminase that inhibits HIV-1 replication. To evade this restriction, the HIV-1 Vif protein binds A3H and mediates its proteasomal degradation. To date, little information on the Vif-A3H interface has been available. To decipher how both proteins interact, we first mapped the Vif-binding site on A3H by functionally testing a large set of A3H mutants in single-cycle infectivity and replication assays. Our data show that the two A3H α-helixes α3 and α4 represent the Vif-binding site of A3H. We next used viral adaptation and a set of Vif mutants to identify novel, reciprocal Vif variants that rescued viral infectivity in the presence of two Vif-resistant A3H mutants. These A3H-Vif interaction points were used to generate the first A3H-Vif structure model, which revealed that the A3H helixes α3 and α4 interact with the Vif β-sheet (β2-β5). This model is in good agreement with previously reported Vif and A3H amino acids important for interaction. Based on the predicted A3H-Vif interface, we tested additional points of contact, which validated our model. Moreover, these experiments showed that the A3H and A3G binding sites on HIV-1 Vif are largely distinct, with both host proteins interacting with Vif β-strand 2. Taken together, this virus-host interface model explains previously reported data and will help to identify novel drug targets to combat HIV-1 infection. HIV-1 needs to overcome several intracellular restriction factors in order to replicate efficiently. The human APOBEC3 locus encodes seven proteins, of which A3D, A3F, A3G, and A3H restrict HIV-1. HIV encodes the Vif protein, which binds to the APOBEC3 proteins and leads to their proteasomal degradation. No HIV-1 Vif-APOBEC3 costructure exists to date despite extensive research. We and others previously generated HIV-1 Vif costructure models with A3G and A3F by mapping specific contact points between both proteins. Here, we applied a similar approach to HIV-1 Vif and A3H and successfully generated a Vif-A3H interaction model. Importantly, we find that the HIV-1 Vif-A3H interface is distinct from the Vif-A3G and Vif-A3F interfaces, with a small Vif region being important for recognition of both A3G and A3H. Our Vif-A3H structure model informs on how both proteins interact and could guide toward approaches to block the Vif-A3H interface to target HIV replication.
人类载脂蛋白B mRNA编辑酶催化多肽样蛋白3H(APOBEC3H,A3H)是一种胞苷脱氨酶,可抑制HIV-1复制。为逃避这种限制,HIV-1病毒感染因子(Vif)蛋白与A3H结合并介导其通过蛋白酶体降解。迄今为止,关于Vif-A3H相互作用界面的信息很少。为了解这两种蛋白质如何相互作用,我们首先通过在单周期感染性和复制试验中对大量A3H突变体进行功能测试,绘制了A3H上的Vif结合位点。我们的数据表明,A3H的两个α螺旋α3和α4代表A3H的Vif结合位点。接下来,我们利用病毒适应性和一组Vif突变体来鉴定新的、相互作用的Vif变体,这些变体在存在两个对Vif耐药的A3H突变体的情况下挽救了病毒感染性。这些A3H-Vif相互作用点用于生成第一个A3H-Vif结构模型,该模型显示A3H螺旋α3和α4与Vifβ折叠(β2-β5)相互作用。该模型与先前报道的对相互作用重要的Vif和A3H氨基酸高度一致。基于预测的A3H-Vif界面,我们测试了其他接触点,验证了我们的模型。此外,这些实验表明,HIV-1 Vif上的A3H和A3G结合位点在很大程度上是不同的,这两种宿主蛋白都与Vif的β链2相互作用。综上所述,这种病毒-宿主界面模型解释了先前报道的数据,并将有助于识别对抗HIV-1感染的新药物靶点。HIV-1需要克服几种细胞内限制因子才能有效复制。人类APOBEC3基因座编码七种蛋白质,其中A3D、A3F、A3G和A3H可限制HIV-1。HIV编码Vif蛋白,该蛋白与APOBEC3蛋白结合并导致其通过蛋白酶体降解。尽管进行了广泛研究,但迄今为止尚无HIV-1 Vif-APOBEC3的共结构。我们和其他人之前通过绘制两种蛋白质之间的特定接触点,生成了HIV-1 Vif与A3G和A3F的共结构模型。在这里,我们对HIV-1 Vif和A3H应用了类似的方法,并成功生成了Vif-A3H相互作用模型。重要的是,我们发现HIV-1 Vif-A3H界面与Vif-A3G和Vif-A3F界面不同,Vif的一个小区域对识别A3G和A3H都很重要。我们的Vif-A3H结构模型揭示了这两种蛋白质如何相互作用,并可指导开发阻断Vif-A3H界面以靶向HIV复制的方法。